

C. Annual Burden

Respondents: 28,399.

Total Annual Responses: 148,094.

Total Burden Hours: 9,160,160.

Obtaining Copies: Requesters may obtain a copy of the information collection documents from the GSA Regulatory Secretariat Division by calling 202-501-4755 or emailing GSARegSec@gsa.gov.

Please cite OMB Control No. 9000-0013, Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data.

William F. Clark,

Director, Office of Government-wide Acquisition Policy, Office of Acquisition Policy, Office of Government-wide Policy.

[FR Doc. 2020-24614 Filed 11-5-20; 8:45 am]

BILLING CODE 6820-EP-P

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-0250; Docket No. 2020-0001; Sequence No. 7]

Information Collection; General Services Administration Acquisition Regulation; Zero Burden Information Collection Reports

AGENCY: Office of the Chief Acquisition Officer, General Services Administration (GSA).

ACTION: Notice of request for public comments regarding an extension to an existing OMB information collection.

SUMMARY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division (MVCB) will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement regarding Zero Burden Information Collection Reports.

DATES: *Submit comments on or before:* December 7, 2020.

ADDRESSES: Written comments and recommendations for this information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT: Mr. Thomas O'Linn, Procurement Analyst, General Services Acquisition Policy, at 202-445-0390 or via email at Thomas.olinn@gsa.gov

SUPPLEMENTARY INFORMATION:

A. Purpose

This information requirement consists of reports that do not impose collection burdens upon the public. These collections require information which is already available to the public at large, or that is routinely exchanged by firms during the normal course of business. A general control number for these collections decreases the amount of paperwork generated by the approval process.

Under clause 552.238-73, "Identification of Electronic Office Equipment Providing Accessibility for the Handicapped," (previous clause number 552.238-70) the offeror is encouraged to identify office equipment, including any special peripheral that will facilitate electronic office equipment accessibility for handicapped individuals in its commercial catalogs and pricelists accepted by the Government.

B. Annual Reporting Burden

None.

C. Public Comments

A 60-day notice published in the **Federal Register** at 85 FR 53003 on August 27, 2020. No comments were received.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405, telephone 202-501-4755. Please cite OMB Control No. 3090-0250, Zero Burden Information Collection Reports, in all correspondence.

Jeffrey A. Koses,

Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.

[FR Doc. 2020-24725 Filed 11-5-20; 8:45 am]

BILLING CODE 6820-61-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Center for Complementary & Integrative Health; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; Clinical and Data Coordinating Center; Applications for NCCIH Multi-Site Clinical Trials of Mind and Body Interventions.

Date: November 30, 2020.

Time: 3:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Center for Complementary and Integrative, DEM II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Pamela Jeter, Ph.D., Scientific Review Officer, Office of Scientific Review, Division of Extramural Activities, NCCIH, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-547, 301-435-2591, pamela.jeter@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: November 2, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24667 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Library of Medicine; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Library of Medicine Special Emphasis Panel; Conflicted SEP.

Date: December 10, 2020.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Video Assisted Meeting.

Contact Person: Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-7077, tsapl@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: November 2, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24669 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Clinical trials for COVID 19 management in older individuals.

Date: December 11, 2020.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496-9374, grimaldim2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: November 2, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-24615 Filed 11-5-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

DATES: Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and Patenting Manager, NHGRI Technology Transfer Office; Telephone (301) 435-7791; Email: anna.solowiej@nih.gov.

SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma Inc.:

NIH ref No.	Patent No. or application No.	Issue date	Filing date	Title
E-282-2012-0-US-01	61/725,949		November 13, 2012	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-PCT-02	PCT/US2013/069686		November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-03	9,765,031	September 19, 2017	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CA-04	2889697		April 27, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-EP-05	13802153.0	TBD	June 01, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CH-12	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-DE-13	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-FR-14	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-GB-15	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IE-16	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IN-06	3733/DELNP/2015		May 1, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-JP-07	6272626	January 12, 2018	May 11, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CN-08	ZL201380069389.9	August 20, 2019	July 3, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-09	10,683,270	June 16, 2020	August 10, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-10	15/674,333	TBD (application allowed)	August 10, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-11	16/870,093		May 8, 2020	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-01	62/171,179		June 4, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-PCT-02	PCT/US2016/035291		June 1, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-EP-05	16/28547.7		June 1, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-08	15/579,123		December 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-09	16/438,850		June 12, 2019	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-US-01	15/061,829		March 4, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-PCT-02	PCT/US2017/020250		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-CN-03	2017800118698		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-EP-04	17711443.6		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-01	61/991,333		May 9, 2014	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-PCT-02	PCT/US2015/029946		May 8, 2015	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-AU-03	2015255765		November 7, 2016	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CA-04	2948349		May 8, 2015	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CN-05	201580028788.X	February 7, 2020	May 8, 2015	Cannabinoid Receptor Mediating Compounds.